Handling a regulatory submission for an orphan drug means following a two-stage process: first applying for orphan designation from the European Medicines Agency (EMA), then pursuing a marketing authorisation that takes advantage of the procedural and incentive framework designed specifically for medicines targeting rare conditions. The process is distinct from standard drug submissions in meaningful ways, and understanding those differences early can save time and resources. Below, we walk through the key questions companies face when navigating orphan drug regulatory submissions in the EU.
What qualifies a drug for orphan designation in the EU?
A drug qualifies for orphan designation in the EU when it targets a life-threatening or chronically debilitating condition affecting no more than five in 10,000 people in the EU, and when either no satisfactory treatment exists or the medicine offers a significant benefit over existing options. Both criteria must be demonstrated at the time of application.
The condition prevalence threshold is assessed against the EU population, which means the absolute number of patients matters. Applicants must provide epidemiological data supporting the prevalence estimate, and these data are scrutinised by the EMA’s Committee for Orphan Medicinal Products (COMP). If a treatment already exists for the condition, the applicant must demonstrate a clinically meaningful advantage, such as greater efficacy, a better safety profile, or a benefit for a patient subgroup that does not respond to current options.
The plausibility of benefit also needs to be supported at the designation stage. This does not require full clinical evidence, but there must be a scientific rationale, typically drawn from non-clinical data, early-phase results, or mechanistic reasoning, showing the medicine could work in the target population.
When should you apply for orphan designation?
You should apply for orphan designation as early as possible in development, ideally before or during Phase II clinical trials. Designation can be sought at any point before the marketing authorisation application is submitted, but applying early allows you to benefit from the associated incentives, including protocol assistance and fee reductions, throughout the development programme.
Early designation also provides strategic clarity. Once granted, the designation confirms the regulatory framework you are operating within and signals to investors and partners that the product has been recognised under the EU orphan medicines framework. There is no obligation to have completed clinical development before applying; the COMP evaluates the application on the basis of available evidence at that time. If you would like to understand how our team approaches designation strategy, visit our services overview for a full picture of what we offer.
One practical consideration: orphan designation and marketing authorisation are separate procedures with separate application dossiers. Securing designation early means you have more time to build the evidence package required for the authorisation stage without conflating the two processes.
What regulatory incentives come with orphan drug status?
Orphan drug status in the EU comes with several significant regulatory incentives, the most valuable being ten years of market exclusivity after approval, during which the EMA will not accept a marketing authorisation application for a similar medicine for the same condition from a competitor. Additional incentives include protocol assistance, fee reductions, and access to the centralised procedure.
The key incentives are:
- Market exclusivity: Ten years post-approval, extendable to twelve years if data from a paediatric investigation plan are submitted and approved.
- Protocol assistance: Scientific advice specifically tailored to orphan medicines, provided at reduced cost, covering both quality and clinical development questions.
- Fee reductions: Significant reductions on EMA application and inspection fees, with small and medium-sized enterprises eligible for additional waivers.
- Centralised procedure access: Orphan medicines are eligible for the centralised procedure, resulting in a single EU-wide authorisation rather than separate national approvals.
- Paediatric rewards: Compliance with paediatric development requirements can extend market exclusivity, providing an additional incentive to include paediatric populations in development planning.
These incentives exist because rare disease drug development is inherently high-risk and commercially challenging. The smaller patient populations make large-scale trials difficult, and the commercial return is often limited. The incentive framework is designed to make development viable despite those constraints.
How does the marketing authorisation process differ for orphan drugs?
The marketing authorisation process for an orphan drug follows the centralised procedure at the EMA and must include a review of the orphan designation criteria at the time of authorisation. The COMP reassesses whether the prevalence and significant benefit criteria are still met, and this review runs in parallel with the scientific evaluation by the Committee for Medicinal Products for Human Use (CHMP).
One notable difference is the flexibility in evidentiary standards. Because rare diseases often make large randomised controlled trials impractical, the EMA accepts adaptive trial designs, smaller sample sizes, surrogate endpoints, and in some cases, extrapolation from related conditions. This does not mean lower standards; it means the evidence is evaluated in the context of what is feasible and scientifically sound for the specific disease.
Applicants are also expected to have engaged with the EMA through protocol assistance before submission. The regulatory submission dossier for an orphan medicine typically reflects years of iterative scientific dialogue, and reviewers expect to see that the development programme was shaped by that feedback. Gaps between protocol assistance guidance and the actual dossier can generate questions during evaluation and slow the process.
What are the biggest regulatory challenges in orphan drug submissions?
The biggest regulatory challenges in orphan drug submissions centre on demonstrating clinical benefit with limited patient numbers, managing uncertainty in the benefit-risk assessment, and satisfying the significant benefit criterion if a comparator treatment exists. These challenges are structural to rare disease development and require careful planning rather than last-minute solutions.
Demonstrating efficacy with small populations
Small patient populations make it difficult to power trials conventionally. Regulators expect applicants to justify their statistical approach and explain how the chosen endpoints reflect meaningful clinical outcomes for patients. Surrogate endpoints may be accepted, but the link between the surrogate and clinical benefit must be well-argued. Natural history data and patient registries become particularly important in this context, both to support trial design and to contextualise results.
Establishing significant benefit over existing treatments
If a treatment already exists for the condition, the applicant must show significant benefit at the marketing authorisation stage, not just at the designation stage. This can become a moving target if the comparator landscape shifts during development. Companies sometimes find that a treatment approved after their designation was granted creates a new comparator they had not planned for. Tracking the therapeutic landscape throughout development and updating the significant benefit argument accordingly is essential.
How do you maintain orphan market exclusivity after approval?
Maintaining orphan market exclusivity after approval requires the marketing authorisation holder to submit an annual report to the EMA confirming that the orphan condition still meets the prevalence criterion and that the significant benefit over any new comparators is maintained. The EMA can review and potentially withdraw exclusivity if these conditions are no longer satisfied.
Practical steps to protect exclusivity include:
- Monitoring the competitive landscape continuously and assessing whether new approvals constitute similar medicines for the same indication.
- Maintaining up-to-date epidemiological data on disease prevalence to confirm the condition still qualifies as rare.
- Documenting post-approval clinical evidence that supports the ongoing significant benefit argument, particularly if new treatment options emerge.
- Engaging proactively with the EMA if the benefit-risk profile of a comparator changes, rather than waiting for the annual review cycle.
It is also worth noting that exclusivity applies to similar medicines for the same indication. A competitor may still receive authorisation for a different indication, a different formulation with a meaningfully different clinical profile, or if they can demonstrate their medicine is clinically superior. Understanding the precise scope of your exclusivity and monitoring for potential challenges is an ongoing regulatory responsibility, not a one-time task.
How Starodub supports orphan drug regulatory submissions
We work with biopharmaceutical companies at every stage of the orphan drug journey, from initial designation strategy through to marketing authorisation and post-approval exclusivity management. Our team brings hands-on experience with EMA procedures and understands how to build a dossier that reflects both the scientific complexity and the regulatory expectations specific to rare disease medicines. To learn more about who we are and the experience we bring to each engagement, visit our company page.
Here is what we provide:
- Orphan designation strategy: Assessing eligibility, preparing the designation application, and building the epidemiological and significant benefit arguments.
- Regulatory pathway planning: Advising on development plans, protocol assistance preparation, and aligning clinical programmes with EMA expectations for rare disease evidence.
- Dossier preparation and submission management: Compiling and reviewing the marketing authorisation application, coordinating responses to CHMP and COMP questions, and managing the submission timeline.
- Post-approval compliance: Supporting annual reporting, monitoring the competitive landscape, and advising on exclusivity maintenance.
- Cross-functional expertise: Drawing on our network of specialists in CMC, clinical, and quality to ensure every section of the dossier meets the required standard.
If you are planning an orphan drug programme or need support with an existing regulatory submission, we would be glad to discuss how we can help. Reach out to our team to start the conversation.
Related Articles
- What is the difference between GMP compliance and GMP certification?
- What regulatory affairs services do medical device companies need?
- What regulatory pathway should startups choose for first medical device approval?
- How do you maintain regulatory compliance after approval?
- How do you determine medical device classification?
This content was generated with the help of AI and it may contain mistakes
